Triple therapy aims to shrink rectal tumors without surgery
NCT ID NCT07154316
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tests whether adding immunotherapy and a COX-2 inhibitor to standard chemoradiotherapy can improve complete remission rates in people with locally advanced rectal cancer that is microsatellite stable (MSS). About 138 participants will receive either long-course or short-course radiation plus the drug combo. The goal is to see if the tumor disappears completely, potentially allowing patients to avoid surgery and keep their rectum.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
capecitabine, oxaliplatin, serplulimab, celecoxib, radiation therapy
What this could lead to
If successful, this combination could offer a more effective, organ-sparing treatment for a common type of rectal cancer, potentially avoiding permanent colostomy.
What could go wrong
This is a mid-stage trial with only 138 participants, so results may not apply to all patients. Adding multiple drugs also raises the risk of serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anyang Tumor Hospital
RECRUITINGAnyang, Henan, 455100, China
Contact Phone: •••-•••-••••
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fujian Provincial Cancer Hospital
RECRUITINGFuzhou, Fujian, 350000, China
Contact Phone: •••-•••-••••
-
The First Affiliated Hospital of Shandong First Medical University
RECRUITINGJinan, Shandong, 250014, China
Contact Phone: •••-•••-••••
-
Yunnan Cancer Hospital
RECRUITINGKunming, 650118, China
Contact Phone: •••-•••-••••